Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H31NO4.ClH |
| Molecular Weight | 494.022 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=C([C@@H](OC2=CC(O)=CC=C12)C3=CC=C(OCCN4CCCCC4)C=C3)C5=CC=C(O)C=C5
InChI
InChIKey=BYQDPIXWTVEVEA-JMAPEOGHSA-N
InChI=1S/C29H31NO4.ClH/c1-20-26-14-11-24(32)19-27(26)34-29(28(20)21-5-9-23(31)10-6-21)22-7-12-25(13-8-22)33-18-17-30-15-3-2-4-16-30;/h5-14,19,29,31-32H,2-4,15-18H2,1H3;1H/t29-;/m0./s1
| Molecular Formula | C29H31NO4 |
| Molecular Weight | 457.5607 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11850228Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/10418981 | http://en.pharmacodia.com/web/drug/1_2035.html | http://adisinsight.springer.com/drugs/800013630
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11850228
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/10418981 | http://en.pharmacodia.com/web/drug/1_2035.html | http://adisinsight.springer.com/drugs/800013630
Acolbifene, the active metabolite of EM-800, was identified as a pure antagonist that acts on both activation domains of the ERs. It is in Phase III clinical trials for the prevention of breast cancer and vasomotor symptoms (Hot flush) in postmenopausal women. Most commonly reported adverse events included irregular menses, leg/muscle cramps, diarrhea, and hot flashes. No serious adverse events were reported.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1287617 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11179460 |
|||
Target ID: CHEMBL3542435 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11179460 |
|||
Target ID: CHEMBL1743319 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11179460 |
|||
Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10418981 |
0.52 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [IC50 7 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| likely | ||||
| major [Km 19 uM] | ||||
| major [Km 63 uM] | ||||
| major [Km 64 uM] | ||||
| major | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068), by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. | 2001-03 |
|
| EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. | 1999-07-27 |
|
| Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. | 1997-08-15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26391916
20 mg daily for 6-8 months
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10418981
As measured by competition studies in human breast cancer tissue, the anity of EM-652 (Ki=0.047 nM, RBA=291, relative to 17b-estradiol set at 100) studied in the presence of ethanol was 2.9 higher than that of estradiol itself (RBA=6.62).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:43 GMT 2025
by
admin
on
Mon Mar 31 18:22:43 GMT 2025
|
| Record UNII |
KXC7811DBY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1821
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
KXC7811DBY
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
LL-83
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
252555-01-4
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL68055
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
C65213
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
300000044626
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
155436
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY | |||
|
DTXSID30948108
Created by
admin on Mon Mar 31 18:22:43 GMT 2025 , Edited by admin on Mon Mar 31 18:22:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |